Trial Profile

Planned Transition to Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy in Renal Allograft Recipients.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary) ; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

08 Nov 2013 Top-line results reported in a Pfizer media release.
08 Nov 2013 Status changed from recruiting to completed, as reported by a Pfizer media release.
08 Nov 2013 Primary endpoint 'significant difference in percentage of patients with an improvement in glomerular filtration rate over 24 months' has not been met, as reported by a Pfizer media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com